• Early breast cancer: no benefit for alpelisib with neoadjuvant letrozole

    Benefit observed in metastatic disease did not extend to early breast cancer.

  • ESMO Breast Cancer conference: de-escalating treatment
    ESMO Breast Cancer conference: de-escalating treatment

    Omitting chemotherapy from the first-line treatment of patients with HER2-positive metastatic breast cancer.

  • EndoPredict predicts chemo benefit in ER-positive HER2-negative breast cancer
    EndoPredict predicts chemo benefit in ER-positive HER2-negative breast cancer

    International research led by Queen Mary University of London.

  • Cochrane: aromatase inhibitors top tamoxifen for breast cancer prevention

    33% additional risk reduction with a different safety profile.

  • ESMO Breast Cancer 2019: continuous vs intermittent chemotherapy for HER2- breast cancer
    ESMO Breast Cancer 2019: continuous vs intermittent chemotherapy for HER2- breast cancer

    Findings from the Stop & Go study presented at the ESMO Breast Cancer congress 2019.

  • Breast cancer: tucidinostat + exemestane delays progression in phase 3

    Adding tucidinostat to exemestane also increased hematologic toxicity.

  • Large-scale, single-cell atlas maps breast cancer ecosystem

    Single cell phenotype shows dominance, correlates with immunoenviroment in aggressive tumors.

  • ESTRO 2019 – Radiotherapy after breast cancer surgery reduces the risk of local disease recurrence in the long-term

    ABCSG8A trial results at 10 years showed a lower risk of recurrence and a longer disease-free survival in early, hormone-driven disease when irradiation was added to anti-hormone treatments.

  • Breast cancer: high serum LDH portends poorer survival

    11 studies with more than 6000 patients show poorer PFS, OS.

  • Breast cancer: radiotherapy yields survival benefit in young women

    Benefit observed across subtypes with the exception of TNBC.

  • Breast cancer prevention: risedronate counters anastrozole-induced bone loss

    Final 5-year analysis of IBIS-II prevention trial in women at high risk for breast cancer.

  • Annual screen benefits young women with family history of breast cancer

    Study of more than 2800 women aged 35-39 years.

  • European Commission approves olaparib for BRCA-positive breast cancer

    Olaparib extends PFS in OlympiAD trial.

  • Breast-conserving surgery: adjuvant therapy safe for close anterior margins

    Similar long-term recurrence rates for nonsurgical vs surgical management.

  • Load more